Cmtx Biotech, Inc.

Publicly observed

Kings Park, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

Item	Value	Source	Status
Country	US	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
City / locality	Kings Park	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
Name	Cmtx Biotech, Inc.	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed
UEI (U.S. federal entity ID)	SQJJQU7ZLMB9	NIH RePORTER (opens in a new tab) 28 Sept 2026	Publicly observed

Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: A Lung-Specific, Sulfonium Lipid Nanoparticle (sLNP) Formulation of Incyclinide for the Treatment of ALI/ARDS
USD 367,988.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Drug Repurposing for the Treatment of Staphylococcus aureus Bacteremia
USD 296,470.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Grant1 Jul 2026Publicly observed
NIH SBIR/STTR award: Novel Small Molecule for the Prevention of Hemorrhagic Cystitis
USD 349,687.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Grant1 Mar 2025Publicly observed
NIH SBIR/STTR award: Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome
USD 887,354.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Grant9 Jul 2024Publicly observed
NIH SBIR/STTR award: A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury
USD 295,715.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.